← All trials
NCT03590600
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2018
- Primary completion
- Oct 11, 2018
- Completion date
- Dec 15, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Ludwig Maximilians UniversitySponsor investigator
- German Federal Ministry of Education and ResearchCollaborator
- German Center for Infection ResearchCollaborator
- Hans Knöll Institute (HKI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.